{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:13:50Z","timestamp":1793103230317,"version":"4.5.0"},"reference-count":47,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ritlecitinib and baricitinib are recently approved systemic treatments for severe alopecia areata (AA). Both demonstrated superiority over placebo in hair regrowth measured by the Severity of Alopecia Tool (SALT), but they have not been directly compared in randomized controlled trials (RCTs). We conducted a systematic review of RCTs evaluating treatments in AA and estimated the efficacy and safety of ritlecitinib and baricitinib at Week 24 using Bayesian network meta\u2010analysis. To adjust and explore effect modifiers, population\u2010adjusted indirect comparison was performed via multilevel network meta\u2010regression (ML\u2010NMR) using ritlecitinib individual patient data (IPD). Co\u2010primary endpoints were SALT \u226420 and SALT \u226410 at Week 24. Unanchored population adjusted ITCs were also computed to evaluate SALT \u226410 and SALT \u226420 endpoints at Week 48\/52. Four RCTs (ALLEGRO 2a [NCT02974868], ALLEGRO 2b\/3 [NCT03732807], BRAVE\u2010AA1 [NCT03570749] and BRAVE\u2010AA2 [NCT03899259]) were included. No evidence of a difference between ritlecitinib 50\u2009mg and baricitinib 4\u2009mg on SALT \u226410 (odds ratio, OR: 0.96, 95% credible interval, CrI: 0.18\u20137.21) and SALT \u226420 (OR: 2.16, 95% CrI: 0.48\u201316.46) at Week 24 was found. ML\u2010NMR using ALLEGRO IPD adjusted for sex, SALT score at baseline, duration of current episode and disease duration found evidence of effect modification, although relative efficacy between ritlecitinib 50\u2009mg and baricitinib 4\u2009mg remained unchanged. Unanchored population\u2010adjusted ITC at Week 48\/52 was consistent with previous results. We found similar efficacy between ritlecitinib 50\u2009mg and baricitinib 4\u2009mg. These ITCs was informed by only four RCTs, uncertainty was considerable, and there was evidence of effect modification, highlighting the need for further quality research in AA.<\/jats:p>","DOI":"10.1111\/jdv.20372","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T12:48:42Z","timestamp":1729774122000},"page":"1134-1142","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata"],"prefix":"10.1111","volume":"39","author":[{"given":"D.","family":"Aceituno","sequence":"first","affiliation":[{"name":"Clifton Insight  Bristol UK"},{"name":"Pontificia Universidad Cat\u00f3lica de Chile  Santiago Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. G.","family":"Fawsitt","sequence":"additional","affiliation":[{"name":"Clifton Insight  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. M.","family":"Power","sequence":"additional","affiliation":[{"name":"Clifton Insight  Bristol UK"},{"name":"MRC Integrative Epidemiology Unit University of Bristol  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6111-8008","authenticated-orcid":false,"given":"E.","family":"Law","sequence":"additional","affiliation":[{"name":"Pfizer Inc  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8606-5304","authenticated-orcid":false,"given":"S.","family":"Vaghela","sequence":"additional","affiliation":[{"name":"HealthEcon Consulting Inc  Ancaster Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Thom","sequence":"additional","affiliation":[{"name":"Clifton Insight  Bristol UK"},{"name":"University of Bristol  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1103442"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.032"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.050"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01293-0"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.04.1142"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01928-y"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00222-2"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110343"},{"key":"e_1_2_11_10_1","unstructured":"NCT03732807.PF\u201006651600 for the Treatment of Alopecia Areata (ALLEGRO\u20102b\/3).2021. [Accessed 2024 Feb 18]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/nct03732807"},{"key":"e_1_2_11_11_1","unstructured":"NCT04517864.Placebo\u2010Controlled Safety Study of Ritlecitinib (PF\u201006651600) in Adults With Alopecia Areata (Allegro2a).2021. [Accessed 2024 Feb 18]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/nct04517864"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.002"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.01.011"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118951651"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.2165\/11537420-000000000-00000"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/rssa.12579"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1700"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906"},{"key":"e_1_2_11_20_1","unstructured":"DiasS WeltonNJ SuttonAJ AdesAE.NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta\u2010analysis of randomised controlled trials. National Institute for Health and Care Excellence (NICE).2011. [Accessed 2024 Feb 18]. Available from:https:\/\/www.sheffield.ac.uk\/nice\u2010dsu"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12458724"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6381"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/1467-9868.00353"},{"key":"e_1_2_11_24_1","unstructured":"DiasS SuttonAJ WeltonNJ AdesAE.Heterogeneity: subgroups meta\u2010regression bias and bias\u2010adjustment.2012."},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780140406"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17725740"},{"key":"e_1_2_11_27_1","unstructured":"PhillippoDM AdesAE DiasS PalmerS AbramsKR WeltonNJ.NICE DSU technical support document 18: methods for population\u2010adjusted indirect comparisons in submission to NICE. National Institute for Health and Care Excellence (NICE).2016. [Accessed 2024 Feb 18]. Available from:https:\/\/www.sheffield.ac.uk\/nice\u2010dsu"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.02.008"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8759"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1511"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8857"},{"key":"e_1_2_11_32_1","unstructured":"PhillippoD.R package \u2018multinma\u2019.CRAN. 2020. [Accessed 2024 Feb 18]. Available from:https:\/\/cran.rstudio.com\/web\/packages\/multinma\/index.html"},{"key":"e_1_2_11_33_1","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2019"},{"key":"e_1_2_11_34_1","unstructured":"Stan Development Team.Stan Modeling Language Users Guide and Reference Manual. Version 2.32. 2023. Available from:https:\/\/mc\u2010stan.org"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.050"},{"key":"e_1_2_11_36_1","first-page":"AB52","article-title":"Long\u2010term efficacy of baricitinib in patients with severe alopecia areata: week 52 results from BRAVE\u2010AA1 and BRAVE\u2010AA2","volume":"87","author":"Kwon O","year":"2022","journal-title":"AAD Conference Presentation"},{"key":"e_1_2_11_37_1","first-page":"AB171","article-title":"Health\u2010related quality of life impact associated with severity of non\u2010scalp symptoms among patients with alopecia areata","volume":"87","author":"Edson\u2010Heredia E","year":"2022","journal-title":"AAD Conference Presentation"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.243"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac059"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/00031305.2016.1154108"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1243556"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.064"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.20351"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15903"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19797"},{"key":"e_1_2_11_46_1","volume-title":"Guidelines for the Economic Evaluation of Health Technologies: Canada \u2014 4th Edition"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12455847"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01310-0"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.20372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T11:47:54Z","timestamp":1748260074000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.20372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/jdv.20372"],"URL":"https:\/\/doi.org\/10.1111\/jdv.20372","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"assertion":[{"value":"2024-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}